Near­ly half of can­cer drugs grant­ed ac­cel­er­at­ed ap­proval didn’t end up show­ing clin­i­cal ben­e­fit — study

Al­most half of can­cer drugs that re­ceived ac­cel­er­at­ed ap­proval didn’t end up im­prov­ing qual­i­ty of life or sur­vival af­ter five years of fol­low-up, Har­vard Uni­ver­si­ty …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER